At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 10 enrolled
Drug / intervention
Ozurdex +1 moredrug
Likely dose
Ozurdex 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of an Intravitreal Dexamethasone Implant on Macular Function in Retinal Vein Occlusion Following Treatment With Intravitreal Anti-VEGF Injections.
In Brief
A Phase 3 clinical trial evaluating Ozurdex for Retinal Vein Occlusion and Macular Edema. Completed, enrolled 10 participants across 1 site.
Detailed Summary
To test the efficacy of a 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular function and recalcitrant macular edema associated with retinal vein occlusion following treatment with 2 or more prior intravitreal anti-VEGF drug injections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion, Macular Edema
CountriesUnited States
CollaboratorsAllergan
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedOct 2011
Primary CompletionJul 2012
Study CompletionFeb 2013
TodayJul 2026
First PostedOct 10, 2011
Enrollment StartOct 1, 2011
Primary CompletionJul 1, 2012
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.7 years ago
Interventions
Ozurdexdrug
0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
Ozurdexdrug
0.7 mg intravitreal DEX implant on first visit then every 16 weeks